Lisata Historical Balance Sheet
LSTA Stock | USD 2.62 0.04 1.55% |
Trend analysis of Lisata Therapeutics balance sheet accounts such as Total Current Liabilities of 8.5 M provides information on Lisata Therapeutics' total assets, liabilities, and equity, which is the actual value of Lisata Therapeutics to its prevalent stockholders. By breaking down trends over time using Lisata Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Lisata Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Lisata Therapeutics is a good buy for the upcoming year.
Lisata Therapeutics Inventory |
|
Lisata |
About Lisata Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Lisata Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Lisata Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Lisata Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Lisata currently owns. An asset can also be divided into two categories, current and non-current.
Lisata Therapeutics Balance Sheet Chart
Add Fundamental
Total Current Liabilities
Total Current Liabilities is an item on Lisata Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Lisata Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Property Plant And Equipment Net
The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.Net Debt
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.Most accounts from Lisata Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Lisata Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lisata Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Lisata Stock refer to our How to Trade Lisata Stock guide.At present, Lisata Therapeutics' Total Current Liabilities is projected to decrease significantly based on the last few years of reporting. The current year's Total Stockholder Equity is expected to grow to about 50.6 M, whereas Total Assets are forecasted to decline to about 43.4 M.
2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 714K | 485K | 305K | 289.8K | Total Assets | 97.0M | 73.0M | 54.7M | 43.4M |
Lisata Therapeutics balance sheet Correlations
Click cells to compare fundamentals
Lisata Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Lisata Therapeutics balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 27.2M | 36.0M | 97.0M | 73.0M | 54.7M | 43.4M | |
Other Current Liab | 1.6M | 2.1M | 2.4M | 3.5M | 4.0M | 3.4M | |
Total Current Liabilities | 6.0M | 3.5M | 4.5M | 6.4M | 6.6M | 8.5M | |
Total Stockholder Equity | 20.8M | 32.5M | 92.3M | 66.6M | 48.1M | 50.6M | |
Property Plant And Equipment Net | 100K | 57K | 62K | 296K | 483K | 458.9K | |
Net Debt | (13.7M) | (15.9M) | (23.9M) | (31.7M) | (22.3M) | (21.2M) | |
Retained Earnings | (417.4M) | (425.6M) | (453.0M) | (507.2M) | (528.1M) | (501.7M) | |
Accounts Payable | 1.5M | 1.0M | 1.9M | 2.7M | 2.4M | 2.4M | |
Non Current Assets Total | 1.2M | 671K | 826K | 1.2M | 770K | 731.5K | |
Common Stock Shares Outstanding | 688.3K | 1.0M | 3.7M | 5.2M | 8.1M | 8.5M | |
Liabilities And Stockholders Equity | 27.2M | 36.0M | 97.0M | 73.0M | 54.7M | 43.4M | |
Non Current Liabilities Total | 624K | 254K | 485K | 327K | 210K | 199.5K | |
Other Current Assets | 815K | 758K | 1.2M | 2.7M | 3.4M | 1.7M | |
Other Stockholder Equity | 438.2M | 458.0M | 545.3M | 573.8M | 576.3M | 605.1M | |
Total Liab | 6.6M | 3.8M | 5.0M | 6.7M | 6.8M | 6.5M | |
Total Current Assets | 26.0M | 35.3M | 96.2M | 71.9M | 53.9M | 56.6M | |
Accumulated Other Comprehensive Income | 2K | (13K) | (70K) | (29K) | (42K) | (44.1K) | |
Common Stock | 11K | 19K | 60K | 8K | 7.2K | 6.8K | |
Non Currrent Assets Other | 1.1M | 614K | 764K | 528K | 24K | 22.8K | |
Cash | 14.0M | 16.5M | 24.6M | 32.2M | 22.6M | 23.7M | |
Cash And Short Term Investments | 25.2M | 34.6M | 95.0M | 69.2M | 50.5M | 53.1M | |
Short Term Investments | 11.1M | 18.1M | 70.3M | 37.1M | 27.9M | 18.7M | |
Other Assets | 309K | 0.0 | 40K | 1.2M | 1.4M | 1.5M | |
Net Invested Capital | 20.8M | 32.5M | 92.3M | 66.6M | 48.1M | 54.6M | |
Capital Stock | 11K | 19K | 60K | 8K | 9.2K | 8.7K | |
Net Working Capital | 20.0M | 31.8M | 91.7M | 65.5M | 47.3M | 54.0M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Lisata Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lisata Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lisata Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lisata Therapeutics Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lisata Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Lisata Stock refer to our How to Trade Lisata Stock guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lisata Therapeutics. If investors know Lisata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lisata Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.51) | Return On Assets (0.29) | Return On Equity (0.44) |
The market value of Lisata Therapeutics is measured differently than its book value, which is the value of Lisata that is recorded on the company's balance sheet. Investors also form their own opinion of Lisata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Lisata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lisata Therapeutics' market value can be influenced by many factors that don't directly affect Lisata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lisata Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lisata Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lisata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.